Loading company
$0.980.0%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 13, 2026
Past performance
- 1W
- -2.9%
- 1M
- -1.7%
- 3M
- +142%
- 6M
- +90.3%
- 1Y
- +6.8%
- 5Y
- -93.9%
$0.980.0%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 13, 2026
The quarter ending September 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Profit | -$9.9M | -$16.4M | +39.66% |
| Profit per share | -$0.20 | -$0.36 | +44.44% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Werewolf Therapeutics, Inc. has no earnings call transcript available.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Therapeutics: Werewolf Therapeutics, Inc., is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions. The Company has leveraged its proprietary PREDATOR ® platform to design conditionally activated INDUKINE TM and INDUCER TM molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Werewolf’s INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. The Company’s most advanced clinical stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors. Werewolf has leveraged positive data from its INDUKINE molecules to advance the development of INDUCER molecules. Werewolf’s first INDUCER development candidates, WTX-1011 and WTX-2022, target STEAP1 for prostate cancer and CDH6 for ovarian and kidney cancer, respectively. To learn more visit www.werewolftx.com.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Werewolf Therapeutics, Inc.’s Item 2.02 8-K filed July 31, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.